Article Type
Article
Changed
Tue, 05/03/2022 - 16:04
Display Headline
Goal Attainment in Patients with Type 2 Diabetes, Part 2
Author(s)
Jones JD
Ter Riet Lb
Andrews C
Powell M
Williams L
Emanuel FS

Article PDF
025090014.pdf
Author and Disclosure Information

Jocelyn D. Jones, PharmD, BCPS, Linh B. ter Riet, PharmD, BCPS, Chenise Andrews, PharmD, Mekia Powell, PharmD, Laronne Williams, PharmD, and Frank S. Emanuel, PharmD

Dr. Jones is an assistant professor of pharmacy practice in the College of Pharmacy and Pharmaceutical Sciences at Florida A&M University, Jacksonville. Dr. ter Riet is a medical outcomes specialist in the global research and development division at Pfizer Inc, Jacksonville, FL. At the time of this study, Dr. Andrews, Dr. Powell, and Dr. Williams were doctors of pharmacy candidates in the College of Pharmacy and Pharmaceutical Sciences at Florida A&M. Dr. Emanuel is an associate professor of pharmacy practice and the director of the Jacksonville practice division at Florida A&M. He is also a fellow of the American Society of Health System Pharmacists.

Issue
Federal Practitioner - 25(9)
Publications
Federal Practitioner
Type 2 Diabetes ICYMI
Topics
Diabetes
Page Number
14
Legacy Keywords
diabetes, type 2, mellitus, cardiovascular disease, cardiovascular, CV, CVD, end-stage renal disease, ESRD, glucose, blood pressure, BP, cholesterol, American Diabetes Association, ADA, hemoglobin A1c, HbA1c, low-density lipoprotein, LDL, lipids, nephropathy, antiplatelet therapy, smoking cessation, statin, statins, simvastatin, goal, attainment, patients, Part 2diabetes, type 2, mellitus, cardiovascular disease, cardiovascular, CV, CVD, end-stage renal disease, ESRD, glucose, blood pressure, BP, cholesterol, American Diabetes Association, ADA, hemoglobin A1c, HbA1c, low-density lipoprotein, LDL, lipids, nephropathy, antiplatelet therapy, smoking cessation, statin, statins, simvastatin, goal, attainment, patients, Part 2
Sections
Clinical Review
Author(s)
Jones JD
Ter Riet Lb
Andrews C
Powell M
Williams L
Emanuel FS
Author(s)
Jones JD
Ter Riet Lb
Andrews C
Powell M
Williams L
Emanuel FS
Author and Disclosure Information

Jocelyn D. Jones, PharmD, BCPS, Linh B. ter Riet, PharmD, BCPS, Chenise Andrews, PharmD, Mekia Powell, PharmD, Laronne Williams, PharmD, and Frank S. Emanuel, PharmD

Dr. Jones is an assistant professor of pharmacy practice in the College of Pharmacy and Pharmaceutical Sciences at Florida A&M University, Jacksonville. Dr. ter Riet is a medical outcomes specialist in the global research and development division at Pfizer Inc, Jacksonville, FL. At the time of this study, Dr. Andrews, Dr. Powell, and Dr. Williams were doctors of pharmacy candidates in the College of Pharmacy and Pharmaceutical Sciences at Florida A&M. Dr. Emanuel is an associate professor of pharmacy practice and the director of the Jacksonville practice division at Florida A&M. He is also a fellow of the American Society of Health System Pharmacists.

Author and Disclosure Information

Jocelyn D. Jones, PharmD, BCPS, Linh B. ter Riet, PharmD, BCPS, Chenise Andrews, PharmD, Mekia Powell, PharmD, Laronne Williams, PharmD, and Frank S. Emanuel, PharmD

Dr. Jones is an assistant professor of pharmacy practice in the College of Pharmacy and Pharmaceutical Sciences at Florida A&M University, Jacksonville. Dr. ter Riet is a medical outcomes specialist in the global research and development division at Pfizer Inc, Jacksonville, FL. At the time of this study, Dr. Andrews, Dr. Powell, and Dr. Williams were doctors of pharmacy candidates in the College of Pharmacy and Pharmaceutical Sciences at Florida A&M. Dr. Emanuel is an associate professor of pharmacy practice and the director of the Jacksonville practice division at Florida A&M. He is also a fellow of the American Society of Health System Pharmacists.

Article PDF
025090014.pdf
Article PDF
025090014.pdf

Issue
Federal Practitioner - 25(9)
Issue
Federal Practitioner - 25(9)
Page Number
14
Page Number
14
Publications
Federal Practitioner
Type 2 Diabetes ICYMI
Publications
Federal Practitioner
Type 2 Diabetes ICYMI
Topics
Diabetes
Article Type
Article
Display Headline
Goal Attainment in Patients with Type 2 Diabetes, Part 2
Display Headline
Goal Attainment in Patients with Type 2 Diabetes, Part 2
Legacy Keywords
diabetes, type 2, mellitus, cardiovascular disease, cardiovascular, CV, CVD, end-stage renal disease, ESRD, glucose, blood pressure, BP, cholesterol, American Diabetes Association, ADA, hemoglobin A1c, HbA1c, low-density lipoprotein, LDL, lipids, nephropathy, antiplatelet therapy, smoking cessation, statin, statins, simvastatin, goal, attainment, patients, Part 2diabetes, type 2, mellitus, cardiovascular disease, cardiovascular, CV, CVD, end-stage renal disease, ESRD, glucose, blood pressure, BP, cholesterol, American Diabetes Association, ADA, hemoglobin A1c, HbA1c, low-density lipoprotein, LDL, lipids, nephropathy, antiplatelet therapy, smoking cessation, statin, statins, simvastatin, goal, attainment, patients, Part 2
Legacy Keywords
diabetes, type 2, mellitus, cardiovascular disease, cardiovascular, CV, CVD, end-stage renal disease, ESRD, glucose, blood pressure, BP, cholesterol, American Diabetes Association, ADA, hemoglobin A1c, HbA1c, low-density lipoprotein, LDL, lipids, nephropathy, antiplatelet therapy, smoking cessation, statin, statins, simvastatin, goal, attainment, patients, Part 2diabetes, type 2, mellitus, cardiovascular disease, cardiovascular, CV, CVD, end-stage renal disease, ESRD, glucose, blood pressure, BP, cholesterol, American Diabetes Association, ADA, hemoglobin A1c, HbA1c, low-density lipoprotein, LDL, lipids, nephropathy, antiplatelet therapy, smoking cessation, statin, statins, simvastatin, goal, attainment, patients, Part 2
Sections
Clinical Review
Article Source

PURLs Copyright

Inside the Article

Article PDF Media